Here we show that the FOXO3-FOXM1 transcription factors are pivotal drivers of response to drugs that target p110α or AKT in ER+ breast cancer models with PIK3CA activating mutations or in drugs that target AKT in models with PIK3CA activating mutation and compromised PTEN expression. The gene discussed is PTEN; the disease is breast carcinoma.